Imperial Innovations Group Regulatory News (IVO)

30 Mar 2007 08:00

Imperial Innovations Group plc30 March 2007 30 March 2007 Imperial Innovations Group plc ("Imperial Innovations") Investment in Cell Medica Limited Imperial Innovations Group plc (AIM: IVO), the technology commercialisation andinvestment company, today announces that it has made a £380,000 seed investmentinto Cell Medica Limited (Cell Medica), a company developing cellulartherapeutics for immuno-compromised patients. The investment was part of anoverall £1.9 million fundraising by the company, alongside private investors andthe Wellcome Trust. Cell Medica is the second company based on IP sourced outside of ImperialCollege London to have received an investment from Imperial Innovations. Gregg Sando, CEO, Cell Medica, said, "Imperial Innovations have been been very helpful to Cell Medica in our earlystage development and we look forward to a continued close partnership aimed atthe commercialisation of proven clinical applications for T cell immunotherapy." Susan Searle, CEO, Imperial Innovations, said, "Due to the strength of the technology and the business model, we have been verykeen to support this company in its early stages and we are confident that theinvestment will accelerate the company's development. " -Ends- For more information contact: Imperial InnovationsSusan Searle, Chief Executive Officer +44 (0)20 7594 6591Lucy Ahfong, Marketing Communications Executive +44 (0)20 7594 6644 Cell Medica LimitedSarah Havens, Company Secretary +44 (0)20 7221 7724 M:CommunicationsPatrick d'Ancona / Eleanor Williamson +44 (0)20 7153 1539 JP Morgan CazenoveSteve Baldwin +44 (0)20 7588 2828 Notes to Editors About Imperial Innovations Imperial Innovations is one of the UK's leading technology transfer andcommercialisation companies. The company was founded in 1986 and its ordinaryshares admitted to trading on the AIM Market of London Stock Exchange plc inJuly 2006, raising £26 million. The company's integrated approach encompassesthe identification of ideas, protection of intellectual property, developmentand licensing of technology and formation, incubation and investment intechnology businesses. A wide range of technologies are commercialised withinthe areas of healthcare, energy, environment and emerging technology trends. Based at Imperial College London, the company has established equity holdings in66 technology businesses and has completed 90 commercial agreements. ImperialInnovations also commercialises technologies originating from outside ImperialCollege through incubation contracts with the Carbon Trust and WRAP and hasrelationships with a number of multinational corporations including BAE Systems. Imperial Innovations has invested in a range of spin-out companies, includingThe Acrobot Company Limited, BioCeramic Therapeutics Limited, Cardiak Limited,Circassia Holdings Limited, deltaDOT Limited, Equinox Pharma Limited, FutureWaves PTE Limited, HeliSwirl Technologies Limited, InforSense Limited, LontraLimited, Midaz Lasers Limited, NanoBioDesign Limited, Nexeon Limited, NovaTheraLimited, Thiakis Limited and Veryan Medical Limited. Imperial Innovations currently holds shares in four technology businesses nowlisted on AIM including the fuel cell company, Ceres Power plc. www.imperialinnovations.co.uk The Wellcome Trust The Wellcome Trust is the largest charity in the UK. It funds innovativebiomedical research, in the UK and internationally, spending around £500 millioneach year to support the brightest scientists with the best ideas. The WellcomeTrust supports public debate about biomedical research and its impact on healthand wellbeing. Website: www.wellcome.ac.uk This information is provided by RNS The company news service from the London Stock Exchange